Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Improvement 88% Improvement Relative Risk Improvement (b) 89% Viral clearance 50% Kulzhanova et al. Favipiravir for COVID-19 LATE Is late treatment with favipiravir beneficial for COVID-19? Retrospective 80 patients in Kazakhstan Greater improvement with favipiravir (p<0.000001) Kulzhanova et al., Favors favipiravir Favors control
Clinical efficacy of the antiviral drug favipiravir in the complex treatment of patients with COVID-19 coronavirus infection
Kulzhanova et al.,
Kulzhanova et al., Clinical efficacy of the antiviral drug favipiravir in the complex treatment of patients with COVID-19..,
Aug 2021   Source   PDF  
  All Studies   Meta
Retrospective 40 favipiravir patients in Kazakhstan and 40 controls, showing faster recovery and viral clearance with treatment.
risk of no improvement, 88.0% lower, RR 0.12, p < 0.001, treatment 3 of 40 (7.5%), control 25 of 40 (62.5%), NNT 1.8, mid-recovery day 7.
risk of no improvement, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 40 (0.0%), control 4 of 40 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
risk of no viral clearance, 50.0% lower, RR 0.50, p = 0.18, treatment 6 of 40 (15.0%), control 12 of 40 (30.0%), NNT 6.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kulzhanova et al., 31 Aug 2021, retrospective, Kazakhstan, peer-reviewed, 10 authors, average treatment delay 6.45 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: COVID-19 - TOPICAL SUBJECT Science & Healthcare, 2021 (Vol. 23) 4 Received: 28 June 2021 / Accepted: 02 August 2021 / Published online: 31 August 2021 DOI 10.34689/SH.2021.23.4.001 UDC 616.40:615.7 CLINICAL EFFICACY OF THE ANTIVIRAL DRUG FAVIPIRAVIR IN THE COMPLEX TREATMENT OF PATIENTS WITH COVID-19 CORONAVIRUS INFECTION Sholpan A. Kulzhanova1, Nurlan Е. Aukenov 2, Maiya E. Konkayeva1, Zauresh K. Smagulova1, Gulnara T. Tuleshova1, Saule B. Maukayeva3, 0000-0002-2679-6399 Nazira Ye. Beisenbieva1, Gulsimzhan O. Turebaeva1, Gaukhar A. Nurakhmetova1, 0000-0002-3279-9350 Aigul M. Utegenova1, 0000-0002-5777-3747 1 NJSC “Astana Medical University”, Nur-Sultan, Republic of Kazakhstan; Ministry of Health of the Republic of Kazakhstan, Nur-Sultan, Republic of Kazakhstan; 3 NJSC “Semey Medical University”, Semey, Republic of Kazakhstan. 2 Abstract Introduction. It is known that most patients with COVID-19 have a disease of mild to moderate severity and can be treated at home. A potential etiotropic drug in the treatment of such patients is favipiravir. To finally decide on the inclusion of this drug in the international recommendations for the treatment of COVID-19, further studies are needed to assess its effectiveness and safety in patients with COVID-19. The aim of the study was to study the clinical efficacy of favipiravir in the complex therapy of patients with moderateseverity COVID-19 coronavirus infection. Materials and methods. A retrospective analysis of 468 medical records of an inpatient patient with a moderate form of coronavirus infection COVID-19, who were treated at the State Clinical Hospital at the Multi-Specialty Medical Center of the Akimat of Nur-Sultan, the Semey Infectious Diseases Hospital, for the period August-October 2020, was carried out. The experimental (main) group consisted of 40 patients with COVID-19 of moderate severity, who, in addition to standard therapy in accordance with the Clinical Protocol for Diagnosis and Treatment "COVID-19 Coronavirus infection (10th edition with changes from 15.07.2020), were prescribed oral favipiravir at a dose of 1600 mg/12 h on day 1, then 600 mg/12 h on the following days, for a total of 7 days. The comparison group (control group) consisted of 40 patients with moderate CVI who did not receive favipiravir. Descriptive statistics were performed with the calculation of the mean (M) and standard deviation (SD) for quantitative variables; percentages were calculated for qualitative variables. Statistical analysis was performed using Microsoft Excel and IBM SPSS Statistics 20.0. P <0.05 was considered statistically significant. Results and discussion. The present study showed that the early initiation of antiviral therapy with Favipiravir, compared with standard therapy without an antiviral drug, in patients with a moderate form of COVID-19 is associated with a statistically significant clinical improvement and a large percentage of virus elimination from the mucous membranes of the upper respiratory tract according to molecular genetic research. In the group of patients receiving favipiravir, complete remission of the disease with normalization of the main clinical parameters and the absence of complaints for 7 days of hospitalization was significantly more often than in..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop